Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Precipio, Inc.PRPO · Entity 7207 | Director | October 27, 2023 | October 31, 2023 |
| Vyome Holdings, IncOBLN · Entity 1824 | Director | September 16, 2020 | September 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Precipio, Inc.
Report date October 27, 2023 · Filed October 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,572 |
Reported balance
After 2023-10-27 transaction · row 1
1 source rowRow 1 · 2023-10-27 · Grant · Acquired 5,174 · Balance 5,572 F1: 5,174 shares of common stock were granted upon the close of business on October 27, 2023 as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: 5,174 shares of common stock were granted upon the close of business on October 27, 2023 as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors.
Vyome Holdings, Inc
Report date September 16, 2020 · Filed September 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Expires 2030-09-16 | Direct | 27,250 |
Reported balance
After 2020-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-16 · Grant · Acquired 27,250 · Balance 27,250 F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock. F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2030-09-16 | Direct | 27,250 |
Reported balance
After 2020-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-16 · Grant · Acquired 27,250 · Balance 27,250 F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock.
F2: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CERO THERAPEUTICS HOLDINGS, INC.
Report date February 14, 2024 · Filed February 16, 2024
Section 16 reporting ended · disclosed 2024-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 43,300 |
Reported balance
After 2024-02-14 transaction · row 1
1 source rowRow 1 · 2024-02-14 · Other · Acquired 43,300 · Balance 43,300 F1: Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 | Direct | 50 |
Reported balance
After 2024-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-14 · Grant · Acquired 50 · Balance 50 F2: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2029-02-14 | Direct | 5,000 |
Reported balance
After 2024-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-14 · Other · Acquired 5,000 · Balance 5,000 F1: Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration.
F2: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date.
SERA PROGNOSTICS, INC.
Report date January 10, 2022 · Filed March 31, 2022
Section 16 reporting ended · disclosed 2022-03-31. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2024 Filed Feb 16, 2024 19:39 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | OtherWarrants · Derivative | 5,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001213900-24-015029 · ownership.xml · derivative · entry 3 Fisher Douglas Carl · CIK 0001572355 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-14 F1 · kind: Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 19:39 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantSeries A Convertible Preferred Stock · Derivative | 50 | $1,000.00 Strike: $10.00 | $50,000.00 |
DisclosureSEC source: 0001213900-24-015029 · ownership.xml · derivative · entry 2 Fisher Douglas Carl · CIK 0001572355 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · kind: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. F2 · derivative.exercise_date: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. F2 · derivative.expiration_date: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 19:39 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | OtherClass A Common Stock | 43,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-015029 · ownership.xml · nonDerivative · entry 1 Fisher Douglas Carl · CIK 0001572355 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,300 F1 · kind: Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration. F1 · price: Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:30 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 5,174 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-112958 · tm2329507-1_4seq1.xml · nonDerivative · entry 1 Fisher Douglas Carl · CIK 0001572355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,572 F1 · price: 5,174 shares of common stock were granted upon the close of business on October 27, 2023 as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 20:40 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 7,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-100814 · tm2326171-4_4seq1.xml · nonDerivative · entry 1 Fisher Douglas Carl · CIK 0001572355 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,954 F1 · price: The 7,954 restricted shares of common stock were granted upon the close of business on September 12, 2023 and vested immediately upon issuance. The restricted shares were issued as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:42 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001104659-23-002760 · tm233036-2_4seq1.xml · derivative · entry 1 Fisher Douglas Carl · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-06 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 22:06 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $1.54 | Not disclosed |
DisclosureSEC source: 0001104659-22-004061 · tm222906-3_4seq1.xml · derivative · entry 1 Fisher Douglas Carl · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-11 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 19:31 UTC | CERO THERAPEUTICS HOLDINGS, INC. PBAX · Entity 8622 | OtherWarrants · Derivative | 5,000 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0000899243-21-039936 · doc4.xml · derivative · entry 3 Fisher Douglas · CIK 0001572355 · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Phoenix Biotech Sponsor, LLC Disclosed balance after: 5,000 Underlying: Class A Common Stock · 5,000 shares Expires not disclosed F1 · kind: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC. F3 · shares: Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. F5 · shares: These warrants underlie 10,000 units of the issuer purchased by the reporting person. F1 · price: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC. F6 · derivative.exercise_date: The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering. F7 · derivative.expiration_date: The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation. F3 · ownership.nature: Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 19:31 UTC | CERO THERAPEUTICS HOLDINGS, INC. PBAX · Entity 8622 | OtherClass B Common Stock · Derivative | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039936 · doc4.xml · derivative · entry 2 Fisher Douglas · CIK 0001572355 · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Phoenix Biotech Sponsor, LLC Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed F4 · derivative.exercise_price: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F1 · kind: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC. F3 · shares: Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. F1 · price: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC. F4 · derivative.exercise_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F4 · derivative.expiration_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F3 · ownership.nature: Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 19:31 UTC | CERO THERAPEUTICS HOLDINGS, INC. PBAX · Entity 8622 | OtherClass A common stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039936 · doc4.xml · nonDerivative · entry 1 Fisher Douglas · CIK 0001572355 · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Phoenix Biotech Sponsor, LLC Disclosed balance after: 10,000 F1 · kind: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC. F2 · shares: These shares underlie 10,000 units of the issuer purchased by the reporting person. F1 · price: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC. F3 · ownership.nature: Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:40 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.22 | Not disclosed |
DisclosureSEC source: 0001104659-21-100863 · tm2124311-5_4seq1.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-08-03 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:32 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-21-000954 · tm211613-2_4seq1.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-01-04 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 23:48 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (Right to Buy) · Derivative | 27,250 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001214659-20-007970 · marketforms-49703.xml · derivative · entry 2 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,250 Underlying: Common Stock · 27,250 shares Expires 2030-09-16 F2 · derivative.exercise_date: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 23:48 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option · Derivative | 27,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-007970 · marketforms-49703.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,250 Underlying: Common Stock · 27,250 shares Expires 2030-09-16 F1 · derivative.exercise_price: Each share of Common Stock underlying the cash-settled Option represents the right to a cash payment equal to the excess, if any, of (i) the Fair Market Value of each such share on the date of exercise over (ii) the exercise price per share set forth in the Notice of Stock Option Grant ($0.77), and such Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. This Option may not be exercised for shares of the Company's Common Stock. F2 · derivative.exercise_date: The Option shall vest as to 1/36th of the shares of Common Stock underlying the Option on each monthly anniversary of the grant date, subject to the Grantee's continued service with the Company through the applicable vesting date. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:31 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 4,000 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001104659-20-081244 · tm2024163d5_4.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-07-02 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:21 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-20-005498 · tm205425-1_4.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-01-16 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 20:30 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock (Restricted Stock Units) | 78,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-004757 · marketforms-45353.xml · nonDerivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,125 F1 · shares: This award will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the annual meeting of the Issuer's stockholders immediately following the grant date. F2 · balance_after: Share amounts do not reflect the impact of a 1-for-10 reverse stock split that became effective after the grant date for the options referenced herein. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:00 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001144204-19-015164 · tv516771_4.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-18 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 23:52 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (Right to Buy) · Derivative | 81,774 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001214659-18-004466 · marketforms-42273.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,774 Underlying: Common Stock · 81,774 shares Expires 2028-06-13 F1 · derivative.exercise_date: This Option becomes exercisable with respect to 100% of the Shares subject to this Option on the earlier of (i) the one-year anniversary of the Date of Grant or (ii) the date of the annual meeting of the Company's stockholders immediately following the Date of Grant. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 21:40 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 77,563 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-004794 · doc4.xml · derivative · entry 2 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,563 Underlying: Common Stock · 77,563 shares Expires 2028-02-16 F2 · derivative.exercise_date: This option shall vest as follows: shall vest in 36 equal monthly installments. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 21:40 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 31,025 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-004794 · doc4.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,025 Underlying: Common Stock · 31,025 shares Expires 2028-02-16 F1 · derivative.exercise_date: This option shall vest as follows: shall vest in 12 equal monthly installments. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:03 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000899243-17-022788 · doc4.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2027-09-26 F1 · derivative.exercise_date: This option shall vest monthly over 3 years. Read SEC document |
| June 06, 2017 Filed Jun 17, 2017 01:25 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (Right to Buy) · Derivative | 36,554 | $0.00 Strike: $9.81 | $0.00 |
DisclosureSEC source: 0001214659-17-004067 · marketforms-39086.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,554 Underlying: Common Stock · 36,554 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests as to 100% of the total shares on June 6, 2018, subject to the reporting person's provision of service to the issuer on the vest date. Read SEC document |
| May 09, 2017 Filed May 10, 2017 01:00 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $11.56 | $0.00 |
DisclosureSEC source: 0001214659-17-003154 · marketforms-38793.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: The option vests as to 2.777% of the total shares monthly, commencing on June 9, 2017, with 100% of the total shares vested on May 9, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 22:49 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (right to buy) · Derivative | 46,500 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001209191-16-149851 · doc4.xml · derivative · entry 1 Fisher Douglas · CIK 0001572355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 46,500 shares Expires 2026-11-09 F1 · derivative.exercise_date: The option vests as to 2.777% of the total shares monthly, commencing on December 9, 2016, with 100% of the total shares vested on November 9, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.